title: Oral iron chelation therapy with deferiprone in patients with Thalassemia Major.
abstract: OBJECTIVE
  To determine the efficacy and adverse effects of deferiprone in patients with Thalassemia Major.
  
  
  METHODS
  A prospective case series study was conducted at the Fatimid Foundation Blood Bank and Haematological Diseases center Lahore. A total of 87 patients entered into the study between September 2005 and November 2006. Deferiprone was given at subsidized rates at a dose of 75/mg/day for seven days. Physical examination and initial Laboratory investigations were done in all patients at the start of the study. Physical and laboratory data were filled on a questionnaire and analyzed using SPSS version 10.0.
  
  
  RESULTS
  Eighty seven patients with mean age of 10.0 +/- 4.33 years (range 4-27 years) were included in the study. Mean follow up was 8 +/- 3.94 months (range 2-12 months). The mean Ferritin at the start of study was 4656 +/- 2052.5 ug/L (range 1200-14630 ug/L) and at the end of study period was 4139 +/- 1710.4 ug/L (range 749-8961) (p < 0.001). Adverse events were joint pains in 10% patients, gastrointestinal symptoms in 11% and no adverse events in 79% patients. There was no evidence of agranulocytosis in any patient.
  
  
  CONCLUSIONS
  Deferiprone was well tolerated, had few adverse effects and was effective in lowering the patient's serum ferritin level.
authors.affiliation: Department of Pathology and Microbiology, The Aga Khan University, Stadium Road, Karachi, Pakistan.
authors.forename: Raihan
authors.initials: R
authors.lastname: Sajid
authors.forename: Farooq
authors.initials: F
authors.lastname: Ghani
authors.forename: Salman
authors.initials: S
authors.lastname: Adil
authors.forename: Mohammad
authors.initials: M
authors.lastname: Khurshid
mesh_terms: D000293:Adolescent; D000328:Adult; D015913:Chelation Therapy; D002648:Child; D002675:Child, Preschool; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010154:Pakistan; D011446:Prospective Studies; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D055815:Young Adult; D017086:beta-Thalassemia / Q000188:drug therapy*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone